Comparison
CJC-1295 vs Ipamorelin
Two growth hormone secretagogues with different receptors and very different evidence. One has Phase 1 hormone data; the other has a published Phase 2 trial that missed its endpoint.
Comparison
BPC-157 vs TB-500
BPC-157 and TB-500 are the two compounds most often named together in discussions of tissue repair, frequently as a pair to be used in combination. Neither is approved for any use. Beyond that shared status, they differ in almost everything that matters: what they are, how they are thought to act, and — most importantly — how much human evidence exists and what kind.
Side by side
Every row is traceable to the linked compound profile. Note that this table has no “best for” row: framing investigational compounds that way reads as a treatment recommendation, so we compare primary areas of research instead.
| Attribute | BPC-157Not FDA approved | TB-500 / Thymosin Beta-4Not FDA approved |
|---|---|---|
| Compound type | Synthetic 15-amino-acid peptide based on a fragment of a gastric protein | Fragment of thymosin β4, a naturally occurring 43-amino-acid actin-binding peptide |
| Primary area of research | Gastrointestinal injury; tendon, ligament and muscle repair in animal models | Ocular surface disease (as topical thymosin β4); dermal and cardiac repair in animal models |
| Proposed mechanism | Angiogenesis via VEGFR2 signalling; interaction with the nitric oxide system | Actin sequestration regulating cell motility; promotion of cell migration |
| Research stage | Clinical Research | Investigational |
| Overall evidence level | PRECLINICAL | EARLY CLINICAL |
| Human clinical evidence | Early-phase trials conducted for inflammatory bowel disease; no results published | Randomised placebo-controlled trials completed — for topical ophthalmic thymosin β4, with mixed results |
| Evidence for musculoskeletal repair | Animal models only. No published controlled human trials identified. | Animal models only. No published controlled human trials identified. |
| Animal research | Extensive, concentrated in a small number of affiliated research groups | Substantial, across wound healing, cornea and cardiac injury models |
| FDA approval | No | No |
| FDA 503A compounding status | Nomination withdrawn | Nomination withdrawn (thymosin beta-4 fragment) |
| Principal open question | Does any of the animal healing data translate to humans, and what does sustained angiogenic stimulation do over time? | Does the fragment reproduce the parent peptide’s activity, and does topical ocular evidence say anything about systemic use? |
The comparison people actually want
The question behind most searches for "BPC-157 vs TB-500" is which one works better for an injury. That question cannot be answered from the published record, because the published record does not contain a controlled human trial of either compound for any musculoskeletal injury.
That is not an evasion. It is the finding. Anywhere you see this comparison resolved confidently in favour of one compound, the resolution is coming from somewhere other than evidence.
Where the two genuinely differ
One of them has a clinical file; it is just not the file people think. Thymosin β4 has completed randomised, placebo-controlled human trials, including Phase III work in neurotrophic keratopathy. All of it is topical, ophthalmic, and conducted with the full 43-amino-acid peptide — not with the TB-500 fragment, and not by injection.
The other has an unpublished one. BPC-157 reached early-phase human trials for inflammatory bowel disease in the 2000s. The results were never published, and the programme did not continue. An unpublished trial is not evidence of efficacy, and the pattern of stopping without publishing is weakly informative in the other direction.
Their mechanisms are unrelated. BPC-157's reported mechanism runs through angiogenesis and nitric oxide signalling. Thymosin β4's runs through actin sequestration and cell migration. The rationale sometimes offered for combining them — complementary mechanisms — is a plausible-sounding hypothesis that nobody has tested in humans.
What they share
Both are unapproved. Both appear among substances whose section 503A compounding nominations FDA lists as withdrawn. Both are sold as research chemicals with no guaranteed identity, purity or sterility. Both have their most widely claimed use supported by their weakest evidence.
How to read the table above
The evidence level column deserves care. TB-500 / thymosin β4 carries EARLY CLINICAL because randomised human trials exist — for ocular surface disease. BPC-157 carries PRECLINICAL because no comparable published human result exists. Neither rating says anything about tendon repair, where both would be rated INSUFFICIENT. Our evidence methodology explains how the levels are assigned and, just as importantly, what they do not mean.
Frequently asked questions
Can BPC-157 and TB-500 be used together?
There is no published human research on combining them. The rationale offered for doing so is mechanistic speculation, and combining two compounds with no human safety data does not produce a compound with more.
Which one has more human evidence?
Thymosin β4 — but the evidence is for a topical eye drop in ocular surface disease, not for the TB-500 fragment and not for systemic use. BPC-157 has no published human efficacy data of any kind.
Is either one FDA approved?
No. Neither is approved for any indication, and both appear among substances whose 503A compounding nominations FDA lists as withdrawn.
Other comparisons
Comparison
Semaglutide vs Tirzepatide vs Retatrutide
One, two and three receptors. Two approved drugs and one investigational compound. What the trials measured, what the labels say, and where the differences actually lie.
Comparison
Tesamorelin vs CJC-1295
Two GHRH analogs with the same upstream mechanism and completely different evidence. What separates an approved medicine from a discontinued research compound.
References
Peptide Insider cites primary sources wherever they exist — regulatory documents, trial registrations and peer-reviewed literature — in preference to secondary summaries.
- 1.U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. FDA, 2026;Page last updated 22 April 2026.Regulatory
- 2.Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model. Clinical Ophthalmology, 2015;9:877–884.
- 3.Sikiric P, Seiwerth S, Rucman R, et al.. Focus on Ulcerative Colitis: Stable Gastric Pentadecapeptide BPC 157. Current Medicinal Chemistry, 2012;19(1):126–132.